Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Smith

Showing results (391-400 of 408) with videos related to

Pageof 41
Sort By:
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Plos Pathogens|December 3, 2010
The subtilisin-like protease AprV2 is required for virulence and uses a novel disulphide-tethered exosite to bind substratesRuth M Kennan, Wilson Wong, Om P Dhungyel, et al.
JAMA|May 22, 2017
Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical TrialPatrick B Murphy, Sunita Rehal, Gill Arbane, et al.
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
Nature Methods|September 1, 2017
Data-analysis strategies for image-based cell profilingJuan C Caicedo, Sam Cooper, Florian Heigwer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.
Nature Communications|November 10, 2016
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationPascal Gellert, Corrinne V Segal, Qiong Gao, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Respirology (Carlton, Vic.)|July 4, 2025
NT-proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point-of-Care and Remote MonitoringCharlotte Durrington, Christian Battersby, Laura Holt, et al.
Pageof 41

Showing results (391-400 of 408) with videos related to

Sort By:
Pageof 41
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Plos Pathogens|December 3, 2010
The subtilisin-like protease AprV2 is required for virulence and uses a novel disulphide-tethered exosite to bind substratesRuth M Kennan, Wilson Wong, Om P Dhungyel, et al.
JAMA|May 22, 2017
Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical TrialPatrick B Murphy, Sunita Rehal, Gill Arbane, et al.
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
Nature Methods|September 1, 2017
Data-analysis strategies for image-based cell profilingJuan C Caicedo, Sam Cooper, Florian Heigwer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.
Nature Communications|November 10, 2016
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationPascal Gellert, Corrinne V Segal, Qiong Gao, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Respirology (Carlton, Vic.)|July 4, 2025
NT-proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point-of-Care and Remote MonitoringCharlotte Durrington, Christian Battersby, Laura Holt, et al.
Pageof 41